Skip to main content
Top
Published in: Journal of Neural Transmission 10/2008

01-10-2008 | Basic Neurosciences, Genetics and Immunology - Original Article

Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements

Authors: Werner J. Schmidt, Heike Lebsanft, Manfred Heindl, Manfred Gerlach, Edna Gruenblatt, Peter Riederer, Andreas Mayerhofer, Dieter K. A. Scheller

Published in: Journal of Neural Transmission | Issue 10/2008

Login to get access

Abstract

Sustained drug delivery providing continuous dopaminergic stimulation is thought to prevent or delay the induction of motor complications (dyskinesia) in Parkinson’s disease, whereas pulsatile administration is supposed to promote them. This study investigated the inducibility of sensitization and abnormal involuntary movements (AIMs), comparing continuous and pulsatile administration of rotigotine with pulsatile administration of 3,4-dihydroxy-l-phenylalanine (l-DOPA) for reference. Rats were unilaterally lesioned with 6 hydroxydopamine (6-OHDA). For pulsatile administration, l-DOPA-methylester (10 mg/kg l-DOPA i.p.) or rotigotine (1 mg/kg i.p.) were administered once or twice daily. For continuous administration, a slow release formulation of rotigotine was injected s.c. at a dose of 1 mg/kg every 48 h (experiment I) or every 24 h (experiment II). Pulsatile administration of rotigotine and l-DOPA caused contraversive rotations increasing progressively upon each successive treatment. AIMs started to occur after the second administration of l-DOPA but hardly after pulsatile rotigotine. Continuous rotigotine increased rotations, which reached a plateau after the second administration. No AIMs were observed under continuous administration. The continuous administration of rotigotine did not induce sensitization or AIMs, suggesting that continuous stimulation of dopaminergic receptors by rotigotine has no propensity to induce dyskinesia in this experimental model.
Literature
go back to reference Alam M, Mayerhofer A, Schmidt WJ (2004) The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by l-DOPA. Behav Brain Res 151:117–124PubMedCrossRef Alam M, Mayerhofer A, Schmidt WJ (2004) The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by l-DOPA. Behav Brain Res 151:117–124PubMedCrossRef
go back to reference Anagnostaras SG, Robinson TE (1996) Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Behav Neurosci 110:1397–1414PubMedCrossRef Anagnostaras SG, Robinson TE (1996) Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Behav Neurosci 110:1397–1414PubMedCrossRef
go back to reference Arnt J, Hyttel J (1984) Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions. Eur J Pharmacol 102:349–354PubMedCrossRef Arnt J, Hyttel J (1984) Differential inhibition by dopamine D-1 and D-2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions. Eur J Pharmacol 102:349–354PubMedCrossRef
go back to reference Bertaina-Anglade V, La Rochelle CD, Scheller DK (2006) Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol 548:106–114PubMedCrossRef Bertaina-Anglade V, La Rochelle CD, Scheller DK (2006) Antidepressant properties of rotigotine in experimental models of depression. Eur J Pharmacol 548:106–114PubMedCrossRef
go back to reference Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 249(Suppl 3):lll/1–lll/5 Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 249(Suppl 3):lll/1–lll/5
go back to reference Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211PubMedCrossRef
go back to reference Cenci MA, Lee CS, Bjorklund A (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694–2706PubMedCrossRef Cenci MA, Lee CS, Bjorklund A (1998) l-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur J Neurosci 10:2694–2706PubMedCrossRef
go back to reference Cenci MA, Whishaw IQ, Schallert T (2002) Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 3:574–579PubMedCrossRef Cenci MA, Whishaw IQ, Schallert T (2002) Animal models of neurological deficits: how relevant is the rat? Nat Rev Neurosci 3:574–579PubMedCrossRef
go back to reference Chase TN (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50:S17–S25PubMedCrossRef Chase TN (1998) Levodopa therapy: consequences of the nonphysiologic replacement of dopamine. Neurology 50:S17–S25PubMedCrossRef
go back to reference Chase TN, Engber TM, Mouradian MM (1994) Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson’s disease. Neurology 44(7 Suppl 6):S15–S18PubMed Chase TN, Engber TM, Mouradian MM (1994) Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson’s disease. Neurology 44(7 Suppl 6):S15–S18PubMed
go back to reference Elshoff JP, Cawello W, Braun M, Horstmann R (2006) Stable plasma concentrations over 24 hours in patients with early-stage Parkinson’s disease after once-daily transdermal administration of rotigotine (Neupro®). Neurology 66:A293 Elshoff JP, Cawello W, Braun M, Horstmann R (2006) Stable plasma concentrations over 24 hours in patients with early-stage Parkinson’s disease after once-daily transdermal administration of rotigotine (Neupro®). Neurology 66:A293
go back to reference Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252(Suppl 4):lV37–lV42 Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson’s disease? J Neurol 252(Suppl 4):lV37–lV42
go back to reference Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987–1041PubMedCrossRef Gerlach M, Riederer P (1996) Animal models of Parkinson’s disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm 103:987–1041PubMedCrossRef
go back to reference Graybiel AM, Canales JJ, Capper-Loup C (2000) Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. TINS 23(10 Suppl):S71–S77PubMed Graybiel AM, Canales JJ, Capper-Loup C (2000) Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. TINS 23(10 Suppl):S71–S77PubMed
go back to reference Grosset D (2006) The rotigotine transdermal patch may provide continuous dopaminergic stimulation in early-stage Parkinson’s disease. ACNR 6:32–34 Grosset D (2006) The rotigotine transdermal patch may provide continuous dopaminergic stimulation in early-stage Parkinson’s disease. ACNR 6:32–34
go back to reference Guldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B (2005) Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 28:106–110PubMedCrossRef Guldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B (2005) Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. Clin Neuropharmacol 28:106–110PubMedCrossRef
go back to reference Herrera-Marschitz M, Ungerstedt U (1984) Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites. Eur J Pharmacol 98:165–176PubMedCrossRef Herrera-Marschitz M, Ungerstedt U (1984) Evidence that apomorphine and pergolide induce rotation in rats by different actions on D1 and D2 receptor sites. Eur J Pharmacol 98:165–176PubMedCrossRef
go back to reference Hirsch EC, Hoglinger G, Rousselet E, Breidert T, Parain K, Feger J et al (2003) Animal models of Parkinson’s disease in rodents induced by toxins: an update. J Neural Transm Suppl 10:89–100 Hirsch EC, Hoglinger G, Rousselet E, Breidert T, Parain K, Feger J et al (2003) Animal models of Parkinson’s disease in rodents induced by toxins: an update. J Neural Transm Suppl 10:89–100
go back to reference Jenner P (2004) Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62:S47–S55PubMed Jenner P (2004) Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62:S47–S55PubMed
go back to reference Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 65:S3–S5PubMedCrossRef Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 65:S3–S5PubMedCrossRef
go back to reference Kehr J, Hu XJ, Goiny M, Scheller DK (2007) Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm. 114:1027–1031PubMedCrossRef Kehr J, Hu XJ, Goiny M, Scheller DK (2007) Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation. J Neural Transm. 114:1027–1031PubMedCrossRef
go back to reference Lane EL, Cheetham SC, Jenner P (2006) Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson’s disease? Exp Neurol 197:284–290PubMedCrossRef Lane EL, Cheetham SC, Jenner P (2006) Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson’s disease? Exp Neurol 197:284–290PubMedCrossRef
go back to reference Lee CS, Cenci MA, Schulzer M, Björklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain 123(Pt 7):1365–1379PubMedCrossRef Lee CS, Cenci MA, Schulzer M, Björklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson’s disease. Brain 123(Pt 7):1365–1379PubMedCrossRef
go back to reference Lim E (2005) A walk through the management of Parkinson s disease. Ann Acad Med Singapore 34:188–195PubMed Lim E (2005) A walk through the management of Parkinson s disease. Ann Acad Med Singapore 34:188–195PubMed
go back to reference Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 15:120–132PubMedCrossRef Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA (2002) Pharmacological validation of behavioral measures of akinesia and dyskinesia in a rat model of Parkinson’s disease. Eur J Neurosci 15:120–132PubMedCrossRef
go back to reference Marin C, Rodriguez-Oroz MC, Obeso JA (2006) Motor complications in Parkinson’s disease and the clinical significance of rotational behavior in the rat: have we wasted our time? Exp Neurol 197:269–274PubMedCrossRef Marin C, Rodriguez-Oroz MC, Obeso JA (2006) Motor complications in Parkinson’s disease and the clinical significance of rotational behavior in the rat: have we wasted our time? Exp Neurol 197:269–274PubMedCrossRef
go back to reference Metz GA, Tse A, Ballermann M, Smith LK, Fouad K (2005) The unilateral 6-OHDA rat model of Parkinson’s disease revisited: an electromyographic and behavioral analysis. Eur J Neurosci 22:735–744PubMedCrossRef Metz GA, Tse A, Ballermann M, Smith LK, Fouad K (2005) The unilateral 6-OHDA rat model of Parkinson’s disease revisited: an electromyographic and behavioral analysis. Eur J Neurosci 22:735–744PubMedCrossRef
go back to reference Morelli M, Fenu S, Cozzolino A, Di Chiara G (1991) Positive and negative interactions in the behavioral expression of D1 and D2 receptor stimulation in a model of Parkinsonism: role of priming. Neuroscience 42:41–48PubMedCrossRef Morelli M, Fenu S, Cozzolino A, Di Chiara G (1991) Positive and negative interactions in the behavioral expression of D1 and D2 receptor stimulation in a model of Parkinsonism: role of priming. Neuroscience 42:41–48PubMedCrossRef
go back to reference Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson’s disease. Trends Neurosci 23:S2–S7PubMedCrossRef Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson’s disease. Trends Neurosci 23:S2–S7PubMedCrossRef
go back to reference Olanow CW, Obeso JA (2000) Preventing levodopa-induced dyskinesias. Ann Neurol 47:S167–S176PubMed Olanow CW, Obeso JA (2000) Preventing levodopa-induced dyskinesias. Ann Neurol 47:S167–S176PubMed
go back to reference Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego, CA Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates, 2nd edn. Academic Press, San Diego, CA
go back to reference Poewe W, Wenning G (2002) Levodopa in Parkinson’s disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Lippincott Williams & Wilkins, Philadelphia, pp 104–115 Poewe W, Wenning G (2002) Levodopa in Parkinson’s disease: mechanisms of action and pathophysiology of late failure. In: Jankovic J, Tolosa E (eds) Parkinson’s disease and movement disorders. Lippincott Williams & Wilkins, Philadelphia, pp 104–115
go back to reference Poewe W, Wenning GK (2000) Apomorphine: an underutilized therapy for Parkinson’s disease. Mov Disord 15:789–794PubMedCrossRef Poewe W, Wenning GK (2000) Apomorphine: an underutilized therapy for Parkinson’s disease. Mov Disord 15:789–794PubMedCrossRef
go back to reference Reynolds NA, Wellington K, Easthope SE (2005) Rotigotine: in Parkinson’s disease. CNS Drugs 19:973–981PubMedCrossRef Reynolds NA, Wellington K, Easthope SE (2005) Rotigotine: in Parkinson’s disease. CNS Drugs 19:973–981PubMedCrossRef
go back to reference Scheller DKA (2006) Extended receptor profile of rotigotine, a non-ergolinic dopamine agonist being investigated in Parkinson’s Disease. Mov Disord 21:S80 Scheller DKA (2006) Extended receptor profile of rotigotine, a non-ergolinic dopamine agonist being investigated in Parkinson’s Disease. Mov Disord 21:S80
go back to reference Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275–331PubMedCrossRef Schwarting RK, Huston JP (1996) The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 50:275–331PubMedCrossRef
go back to reference Siever L, Cohen R, Pert A (1981) Assessing pharmacologically induced dopamine receptor sensitivity changes with the Ungerstedt turning model. Psychopharmacology (Berl) 75:212–213CrossRef Siever L, Cohen R, Pert A (1981) Assessing pharmacologically induced dopamine receptor sensitivity changes with the Ungerstedt turning model. Psychopharmacology (Berl) 75:212–213CrossRef
go back to reference Srinivasan J, Schmidt WJ (2004) Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence. Behav Brain Res 154:353–363PubMedCrossRef Srinivasan J, Schmidt WJ (2004) Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence. Behav Brain Res 154:353–363PubMedCrossRef
go back to reference Stocchi F, Olanow CW (2004) Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology 62:S56–S63PubMedCrossRef Stocchi F, Olanow CW (2004) Continuous dopaminergic stimulation in early and advanced Parkinson’s disease. Neurology 62:S56–S63PubMedCrossRef
go back to reference Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62:905–910PubMedCrossRef Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62:905–910PubMedCrossRef
go back to reference Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485–493PubMedCrossRef Ungerstedt U, Arbuthnott GW (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24:485–493PubMedCrossRef
Metadata
Title
Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements
Authors
Werner J. Schmidt
Heike Lebsanft
Manfred Heindl
Manfred Gerlach
Edna Gruenblatt
Peter Riederer
Andreas Mayerhofer
Dieter K. A. Scheller
Publication date
01-10-2008
Publisher
Springer Vienna
Published in
Journal of Neural Transmission / Issue 10/2008
Print ISSN: 0300-9564
Electronic ISSN: 1435-1463
DOI
https://doi.org/10.1007/s00702-008-0102-z

Other articles of this Issue 10/2008

Journal of Neural Transmission 10/2008 Go to the issue

Parkinson's Disease and Allied Conditions - Review Article

Neuroproteomics as a promising tool in Parkinson’s disease research